ATE324913T1 - Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens - Google Patents

Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens

Info

Publication number
ATE324913T1
ATE324913T1 AT99939113T AT99939113T ATE324913T1 AT E324913 T1 ATE324913 T1 AT E324913T1 AT 99939113 T AT99939113 T AT 99939113T AT 99939113 T AT99939113 T AT 99939113T AT E324913 T1 ATE324913 T1 AT E324913T1
Authority
AT
Austria
Prior art keywords
plasmid
complex
nucleic acid
acid vector
formulation agent
Prior art date
Application number
AT99939113T
Other languages
English (en)
Inventor
Maria Bruno
Jenna Tagliaferri
Luke Lawson
Mark J Logan
Russ Mumper
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Application granted granted Critical
Publication of ATE324913T1 publication Critical patent/ATE324913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/789—Of specified organic or carbon-based composition in array format
    • Y10S977/79—Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
    • Y10S977/791—Molecular array
    • Y10S977/792—Nucleic acid array, e.g. human genome array
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
AT99939113T 1998-08-14 1999-08-10 Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens ATE324913T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9657298P 1998-08-14 1998-08-14

Publications (1)

Publication Number Publication Date
ATE324913T1 true ATE324913T1 (de) 2006-06-15

Family

ID=22258010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99939113T ATE324913T1 (de) 1998-08-14 1999-08-10 Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens

Country Status (8)

Country Link
US (1) US6534483B1 (de)
EP (1) EP1104309B8 (de)
JP (1) JP4538150B2 (de)
AT (1) ATE324913T1 (de)
AU (1) AU5345999A (de)
CA (1) CA2340416C (de)
DE (1) DE69931166T2 (de)
WO (1) WO2000009086A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426582A1 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
WO2003086494A1 (en) * 2002-04-05 2003-10-23 Baxter International Inc. Storage stable liquid sealer protein complex
CA2521174C (en) * 2003-03-31 2013-03-12 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Enhanced hiv-1 vaccines and methods for their use
WO2005113147A2 (en) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
WO2005112894A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
MXPA06012989A (es) * 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
US20060003308A1 (en) * 2004-05-12 2006-01-05 Bio-Rad Laboratories, Inc. Electrocompetent cells prepackaged for electroporation
JP4820979B2 (ja) * 2004-10-12 2011-11-24 国立大学法人広島大学 細胞培養装置
EP2056883B1 (de) 2006-08-04 2021-09-22 Baxter International Inc. Zusammensetzung auf mikrokügelchenbasis zur vorbeugung und/oder abwendung einer neuerkrankung an autoimmunem diabetes
ES2660846T3 (es) * 2007-09-28 2018-03-26 Engene, Inc. Composiciones poliplex de quitosano-ácido nucleico de alta concentración
EP2306978A2 (de) * 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Zusammensetzungen zur abgabe von rnai-mitteln in vivo
BRPI1012951A2 (pt) 2009-06-09 2016-07-26 Defyrus Inc "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012076441A1 (en) 2010-12-07 2012-06-14 F. Hoffmann-La Roche Ag Feed mixing device and its use
EP3249054A1 (de) 2012-12-20 2017-11-29 Biomatrica, INC. Formulierungen und verfahren zur stabilisierung von pcr-reagenzien
JP6609246B2 (ja) * 2013-06-28 2019-11-20 エスリス ゲーエムベーハー 細胞内へのｒｎａ導入用組成物
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
BR112018011639A2 (pt) 2015-12-08 2018-11-27 Biomatrica Inc redução de taxa de sedimentação de eritrócitos
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CA3205588A1 (en) * 2020-12-21 2022-06-30 Pfizer Inc. Methods and systems for improved cell transfection
WO2023064187A1 (en) * 2021-10-13 2023-04-20 Life Technologies Corporation Scalable systems and methods for continuous transfection of cells
US20230313232A1 (en) * 2022-02-28 2023-10-05 Corning Incorporated Methods and systems for real-time, continuous production of non-viral carrier nucleic acid particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5164598A (en) * 1985-08-05 1992-11-17 Biotrack Capillary flow device
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
US5738898A (en) * 1995-03-31 1998-04-14 Board Of Trustees Operating Michigan State University Process for reducing sterols in eggs
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US5686071A (en) 1995-06-06 1997-11-11 Per Immune Holdings, Inc. Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US5763158A (en) * 1997-02-06 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Detection of multiple antigens or antibodies
AU1275899A (en) 1997-10-24 1999-05-17 Megabios Corporation Methods for preparing polynucleotide transfection complexes
US6537813B1 (en) 1998-02-13 2003-03-25 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
CN100471522C (zh) * 1998-03-13 2009-03-25 惠氏 聚核苷酸组合物及其制备方法与用途

Also Published As

Publication number Publication date
EP1104309B8 (de) 2006-07-05
EP1104309A2 (de) 2001-06-06
CA2340416A1 (en) 2000-02-24
US6534483B1 (en) 2003-03-18
AU5345999A (en) 2000-03-06
WO2000009086A2 (en) 2000-02-24
WO2000009086A3 (en) 2000-06-08
CA2340416C (en) 2009-06-02
DE69931166T2 (de) 2007-02-15
JP4538150B2 (ja) 2010-09-08
EP1104309B1 (de) 2006-05-03
DE69931166D1 (de) 2006-06-08
JP2002522468A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
ATE324913T1 (de) Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
WO2004084950A3 (en) Cell targeting methods and compositions
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
TR199701071T2 (xx) Aktif madde ulaştırmaya mahsus bileşikler ve terkipler.
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
EP1283054A4 (de) Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
WO2005020958A3 (en) Aerosol delivery of curcumin
BG106046A (en) Pharmaceutical compositions of ertythropoietin
WO2019147743A8 (en) Structure-guided chemical modification of guide rna and its applications
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
HUT63374A (en) Process for producing new benzoic acid derivatives having cardiovascular activity and pharmaceutical compositions comprising such active ingredient
JOP20220006A1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
WO2003041682A3 (en) Lipid carrier compositions and methods for improved drug retention
CA2359491A1 (en) Mixture of plant treatment compositions with waxes, their preparation, and their use
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
TR199902748T2 (xx) Uzun s�re etkili antimikrobik maddelerle ilgili geli�meler
WO2004043993A3 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
WO2001068676A3 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel
CA2534565A1 (en) Reconstitution medium for protein and peptide formulations
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
SI1200088T1 (en) Paracetamol and drotaverine containing composition
CA2481965A1 (en) Aqueous formulations of (2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1104309

Country of ref document: EP